Skip to content
WealthTicker
Back to screener
EquitySectoral/ ThematicDirectIDCWVery High
Invesco logo

Invesco India Pharma and Healthcare Fund

Invesco Mutual Fund · Best Sectoral & Thematic Mutual Funds

NAV
₹10.65
+0.57% 1D
as of 19 Nov 2026

Performance

+6.29%absolute
52-week rangePrev NAV ₹10.59
Latest ₹10.65
Low ₹8.95100th percentile of its 52-week rangeHigh ₹10.65

Key Metrics

3.30%
Direct 3.30% · Regular 5.19%
Category —
69.16
Category —
—
Category —

Scheme Info

Definitions
Plan
Direct · IDCW
None
Up to 0.50%
tiered — see the full terms
0.005%
SIP Inv.
Allowed
₹100
₹1,000
BSE Healthcare TRI
07 Sep 2026

Period returns (<1Y, absolute — not annualized)

Definitions
+18.33%
—
—
—

Annualized returns (≥1Y — CAGR)

Definitions
—
—
—
—
+6.29%
Advanced metrics — risk and benchmark ratios

Fund vs category average (Sectoral/ Thematic)

PeriodFundCategory avg.Diff
1M abs+18.33%——
3M abs———
6M abs———
1Y CAGR———
3Y CAGR———
5Y CAGR———

Category average across peers in Sectoral/ Thematic, same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).

Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.

Backtest this fund

What a SIP or one-time investment would have grown to over this fund’s real NAV history.

Period
Invested
₹20.00K
Current value
₹21.83K
Absolute
+9.17%
XIRR
+626.72%
Value vs. invested
ValueInvested

2 monthly installments of ₹10,000 into Invesco India Pharma and Healthcare Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.

History points
47
Expense ratio
3.30%
AUM
₹110.81Cr
Portfolio turnover
0%
Exit load
^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax
Portfolio, AUM & scheme details shown from another plan of this scheme (same underlying portfolio).
P/E ratio
69.2
P/B ratio
12.3
Avg market cap
₹1,20,021Cr
P/E & P/B are portfolio-weighted harmonic means across 13 of 15 equity holdings (82% of the portfolio); loss-making companies are excluded.

Taxation

Taxed as equity

This is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.

Short-term (STCG)
20%
Held under 1 year

Flat, on the whole gain

Long-term (LTCG)
12.5%
Held 1 year or more

On gains above ₹1.25 L per financial year

Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.

Asset allocation

As on 31 Oct 2026 · AMC disclosure
  • Equity97.04%
  • Cash & Equivalents2.96%
Invesco Mutual Fund logo

AMC Profile

Invesco Mutual Fund is the Indian arm of Invesco, the US asset manager. It began life as Lotus India Mutual Fund, was bought by Religare in 2008 and ran as Religare Invesco until Invesco took full ownership in 2016.

Launched
23 Jul 2006
Total AUM
₹1,64,687Cr+12.8% QoQ
Avg AUM · July - September 2026

Fund Managers

AKAditya KhemaniManaging since 07 Sep 2026
Role

EVP & Fund Manager - Equity

Total experience

More than 20 years

Education

B.Com., PGDM - Finance (IIM, Lucknow)

Experience

November 1, 2023 onwards Invesco Asset Management (India) Pvt. Ltd. July 24, 2019 to October 31, 2023 EVP & Fund Manager - Equity - Motilal Oswal Asset Management India Company Limited October 1, 2007 to July 23, 2019 SVP and Fund Manager - Equity - HSBC Asset Management (India) Pvt. Ltd.

All schemes Aditya Khemani runs →

Fund managers from the AMC's filed Scheme Summary — its most recent filing for this scheme. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.

Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.

About Sectoral & Thematic funds

Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.

Frequently asked questions

What is the NAV of Invesco India Pharma and Healthcare Fund?

As of 19 Nov 2026, the NAV of Invesco India Pharma and Healthcare Fund is ₹10.65 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

What returns has Invesco India Pharma and Healthcare Fund delivered?

Invesco India Pharma and Healthcare Fund has returned +6.29% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

What is the expense ratio of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund charges an expense ratio of 3.30% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

What are the top holdings of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund's largest holdings are Apollo Hospitals Enterprise Limited (9.1%), Divi's Laboratories Limited (8.7%), Max Healthcare Institute Limited (8.6%), Sai Life Sciences Limited (8.5%) and Sun Pharmaceutical Industries Limited (8.3%). Holdings are disclosed monthly and change over time.

How risky is Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund sits at the very high level on our estimate of SEBI's risk-o-meter scale, its trailing-3Y volatility (annualised) is 18.9% and its worst peak-to-trough fall in our sample was 11.4%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

What is the benchmark of Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is benchmarked against the BSE Healthcare TRI. The alpha, beta and capture figures on this page are measured against the Nifty Healthcare TRI, the closest index whose daily history we hold.

Who manages Invesco India Pharma and Healthcare Fund?

Invesco India Pharma and Healthcare Fund is managed by Aditya Khemani at Invesco.

When was Invesco India Pharma and Healthcare Fund launched, and what is its objective?

Invesco India Pharma and Healthcare Fund was launched on 07 Sep 2026. its stated objective is: To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved. Both are as filed in the scheme's own Scheme Summary Document.

How is Invesco India Pharma and Healthcare Fund taxed?

Invesco India Pharma and Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.